Prevalence of Alpha-1 Antitrypsin Deficiency in Non-Cirrhotic Liver Cancer
This research is exploring a possible connection between a genetic condition called Alpha-1 Antitrypsin Deficiency (AATD) and a type of liver cancer known as hepatocellular carcinoma (HCC). People with AATD are already known to have a higher risk of liver cancer, even if their liver isn't severely scarred (non-cirrhotic). This study focuses specifically on HCC in individuals who don't have cirrhosis and no other clear reasons for getting liver cancer. By looking at samples from a group of French patients, the researchers aim to identify specific genetic changes related to AATD using advanced testing. The goal is to better understand if AATD plays a role in causing liver cancer in these particular patients, which could help in earlier diagnosis or prevention strategies in the future.
At a glance
What is this study about?
Imagine your liver as a filter for your body. Sometimes, things can go wrong with this filter, leading to conditions like liver cancer. This study is looking into a genetic condition called Alpha-1 Antitrypsin Deficiency (AATD). People with AATD don't produce enough of a protective protein, which can affect their lungs and liver. We already know that AATD can significantly increase the risk of developing a type of liver cancer called hepatocellular carcinoma (HCC).
What's particularly interesting about this study is its focus. It's looking at people who developed HCC even though their liver wasn't severely scarred (a condition known as cirrhosis). Cirrhosis is a common cause of liver cancer, so finding HCC without it suggests there might be other underlying reasons. The researchers want to see if AATD is one of those reasons when other common causes of liver disease have been ruled out.
To do this, scientists will look at samples from a group of patients in France who developed HCC in a liver that wasn't cirrhotic and didn't have other known risk factors. They will check for specific genetic changes related to AATD using a special lab test. By doing this, they hope to get a clearer picture of whether AATD contributes to this type of liver cancer and how strong that connection might be.
Key takeaways
- This study is looking for a link between a genetic condition (AATD) and liver cancer.
- It focuses on a specific type of liver cancer (HCC) in livers without severe scarring.
- The research uses existing medical information and samples, so no new tests are needed for participants.
- The findings could help understand new causes of liver cancer and improve future care.
- Your contribution could make a difference for others with liver cancer.
Who may be eligible?
This study is looking for adults aged 18 or over. You would need to have been diagnosed with a specific type of liver cancer called hepatocellular carcinoma (HCC). Importantly, your liver should either be healthy or have only minor to moderate scarring, not severe scarring (cirrhosis), outside of the cancerous area. Also, you shouldn't have other well-known causes for your liver disease or cancer, such as heavy alcohol use, certain viral infections like hepatitis, or other specific genetic conditions like hemochromatosis.
You wouldn't be able to join if you are under 18, or if your liver cancer diagnosis isn't clearly confirmed. If your liver has advanced scarring or if you have any of the other known causes for liver disease or cancer mentioned above, you would not be eligible to take part. Also, to participate, you would need to give your informed consent, meaning you understand the study and agree to be part of it.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with a specific type of liver cancer called HCC?
- Was your liver not severely scarred (cirrhotic) at the time of your cancer diagnosis?
- Do you not have other common causes for liver disease or cancer (like heavy drinking or hepatitis)?
What does participation involve?
As this is a retrospective study, it means the researchers are looking back at information and samples that have already been collected from patients. You wouldn't need to attend any extra appointments or have new tests or procedures done specifically for this study. Your participation would involve allowing the research team to use existing information from your medical records and possibly samples (like tissue from your previous liver biopsy) that were collected as part of your standard medical care in the past. There are no new medications or follow-up visits involved for this research.
Potential risks and benefits
Locations (1)
- CHU BordeauxVerified postcodeBordeaux, France
Common questions
What is Alpha-1 Antitrypsin Deficiency (AATD)?
It's a genetic condition where your body doesn't make enough of a protein that protects your lungs and liver.
What is hepatocellular carcinoma (HCC)?
It's the most common type of primary liver cancer.
What does 'non-cirrhotic liver' mean?
It means the liver does not have severe scarring, which is often a cause of liver cancer.
Will I need to go to any appointments for this study?
No, this study uses existing information and samples, so you won't need new appointments.
Is my personal information safe?
Yes, all your information will be kept private and handled confidentially.
How to find out more
Marie Decraecker, MD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.